JALYN GOOLSBY: Open Payments
NPI 1750838066 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,205 in 73 payments from 14 companies in 2025. Trend: 2023 $1,020 · 2024 $1,034 · 2025 $1,205
Food & beverage: $1,205
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $284 |
| Teva Pharmaceuticals USA, Inc. | 14 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $138 |
| Vanda Pharmaceuticals Inc. | 4 | $124 |
| E.R. Squibb & Sons, L.L.C. | 6 | $104 |
| ABBVIE INC. | 3 | $62 |
| Lundbeck LLC | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 2 | $37 |
Products named: ARISTADA, UZEDY, CAPLYTA, FANAPT, COBENFY, ABILIFY ASIMTUFII, VRAYLAR, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
